Subtype‐Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study
Author:
Affiliation:
1. Department of NeurologyGraduate School of MedicineUniversity of Tokyo Tokyo Japan
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1561
Reference28 articles.
1. Importance of inhibiting sodium‐glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis;Kimura G;J Am Soc Hypertens,2016
2. An update on sodium‐glucose co‐transporter‐2 inhibitors for the treatment of diabetes mellitus;Hsia DS;Curr Opin Endocrinol Diabetes Obes,2017
3. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and stroke;Kimura G;Circ J,2017
4. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA‐REG OUTCOME® trial;Fitchett D;Eur Heart J,2016
5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials;Zelniker TA;Lancet,2019
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. APOE-ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapy;Frontiers in Dementia;2024-01-15
2. Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes;Diabetes Epidemiology and Management;2024-01
3. Neuroprotective potential of gliflozins;Diabetes mellitus;2023-11-16
4. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies;Diabetes & Metabolism;2023-09
5. Differential effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose–response meta-analysis involving 10 randomized clinical trials and 71 553 individuals;European Journal of Endocrinology;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3